About argenx
argenx is a company based in Ghent (Belgium) founded in 2008.. argenx has raised $61.9 million across 11 funding rounds from investors including Crédit Agricole, Orbimed and PMV. The company has 355 employees as of December 31, 2022. argenx operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Forge Biologics and Erasca, among others.
- Headquarter Ghent, Belgium
- Employees 355 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$1.41 B (USD)28as on Dec 31, 2022
-
Net Profit
$-527.76 M (USD)-32as on Dec 31, 2022
-
EBITDA
$211.72 M (USD)81as on Dec 31, 2022
-
Total Equity Funding
$61.9 M (USD)
in 11 rounds
-
Latest Funding Round
$700 M (USD), Post-IPO
Mar 24, 2022
-
Investors
Crédit Agricole
& 13 more
-
Employee Count
355
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
81 people
Software Development Team
67 people
Senior Team
34 people
Product Management Team
24 people
Clinical Team
21 people
Finance and Accounting
18 people
Operations Team
17 people
Human Resources and Administration
13 people
Unlock access to complete
Funding Insights of argenx
argenx has successfully raised a total of $61.9M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $700 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $700.0M
-
First Round
First Round
(09 Sep 2009)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2022 | Amount | Post-IPO - argenx | Valuation |
investors |
|
| May, 2020 | Amount | Post-IPO - argenx | Valuation |
investors |
|
| Nov, 2019 | Amount | Post-IPO - argenx | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in argenx
argenx has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Crédit Agricole, Orbimed and PMV. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private debt funds are managed across multiple sectors.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Early-stage life sciences & tech focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by argenx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - argenx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Argenx Comparisons
Competitors of argenx
argenx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Forge Biologics and Erasca, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Argenx
Frequently Asked Questions about argenx
When was argenx founded?
argenx was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is argenx located?
argenx is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Is argenx a funded company?
argenx is a funded company, having raised a total of $61.9M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $484M, raised on Sep 09, 2009.
How many employees does argenx have?
As of Dec 31, 2022, the latest employee count at argenx is 355.
What is the annual revenue of argenx?
Annual revenue of argenx is $1.41B as on Dec 31, 2022.
What does argenx do?
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llamas and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
Who are the top competitors of argenx?
argenx's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
Who are argenx's investors?
argenx has 14 investors. Key investors include Crédit Agricole, Orbimed, PMV, VIB, and European Union.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.